Colorectal Adenocarcinoma

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (+)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab
Sensitivity (+)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
Sensitivity (+)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Oxaliplatin
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
Sensitivity (+)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Panitumumab
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (+)	KRAS p.G12C	Colorectal Adenocarcinoma	Adagrasib, Cetuximab
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Nivolumab
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Nivolumab
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (+)	EGFR positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab